TNFRSF4 and neoplasm: Agonistic OX‐40 antibodies currently under clinical studies are effective in stimulating T cell activation and proliferation for enhanced anti‐tumor activity,[87] while the corresponding stimulatory receptor OX‐40 molecules can be downregulated on T cells in TME.